Objective: To determine if free beta-human chorionic gonadotropin (hCG) serum levels at the 10th-14th week of gestation were different in groups of women who had experienced pregnancy complications.

Study Design: The obstetric records of women who had uncomplicated pregnancies when they consented to donate blood for biochemical research purposes early in pregnancy were reviewed. Two hundred thirteen of these women had donated blood at the 10th-14th week of gestation. Of these, 135 had uneventful pregnancies and delivered at term, 19 delivered before 37 weeks'gestation, 10 had fetuses small for gestational age, 4 developed pregnancy-induced hypertension, 7 developed gestational diabetes, 10 aborted spontaneously, 4 had an intrauterine fetal death after 20 weeks' gestation, and 24 were lost to follow-up. After the clinical groups had been identified, the 213 maternal serum stored samples were thawed and free beta-hCG measured by enzyme-linked immunosorbent assay. After normalization of the data, ANOVA was used to compare mean gestational age and mean free beta-hCG levels within groups.

Results: The overall mean gestational age at maternal blood sampling was 12.5 weeks. All groups had similar gestational ages at blood sampling (P = .18). The overall mean free beta-hCG serum level was 18.05 mIU/mL. Only the group of women who went on to experience spontaneous abortions had significantly lower free beta-hCG lev- els (mean, 10.45 mIU/mL; P < .03)

Conclusion: Our data suggest that of the groups with obstetric complications evaluated, only the group of women who experienced spontaneous abortions had significantly different serum levels of free beta-hCG at the 10th-14th week of gestation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

free beta-hcg
24
week gestation
16
10th-14th week
12
gestational age
12
maternal serum
8
beta-hcg levels
8
uncomplicated pregnancies
8
obstetric complications
8
serum levels
8
women experienced
8

Similar Publications

(1) Background: Fetal chromosomal examination is a critical component of modern prenatal testing. Traditionally, maternal serum biomarkers such as free β-human chorionic gonadotropin (Free β-HCG) and pregnancy-associated plasma protein A (PAPPA) have been employed for screening, achieving a detection rate of approximately 90% for fetuses with Down syndrome, albeit with a false positive rate of 5%. While amniocentesis remains the gold standard for the prenatal diagnosis of chromosomal abnormalities, including Down syndrome and Edwards syndrome, its invasive nature carries a significant risk of complications, such as infection, preterm labor, or miscarriage, occurring at a rate of 7 per 1000 procedures.

View Article and Find Full Text PDF

To evaluate the association between gestational diabetes mellitus (GDM), including insulin-dependent GDM with pregnancy-associated plasma protein-A (PAPP-A) multiples of the median (MoM) and free beta human chorionic gonadotropin (free β-hCG) MoM levels, and to assess their potential as predictive risk factors. This retrospective study included 2588 women with singleton pregnancies who underwent combined first-trimester screening, along with the 50 g glucose challenge test (GCT) and a 100 g oral glucose tolerance test (OGTT) between 24 and 28 weeks of gestation. Patients were initially divided into four groups based on the glucose screening results, and PAPP-A and free β-hCG MoMs were compared between these groups.

View Article and Find Full Text PDF

Introduction: We evaluated the prognostic potential of the Beta-human chorionic gonadotropin (β-hCG), Carbohydrate Antigen 19-9 (CA19-9), Cancer Antigen 125 (CA125), and Carcinoembryonic Antigen (CEA) tumor markers for bladder cancer.

Methods: We analyzed the records of 369 patients who underwent radical cystectomy for urothelial cancer (UC) between October 2012 until December 2019. Levels of CA19-9, CA125, CEA, and β-hCG before radical cystectomy were measured in all patient samples, and serum biomarker cutoff values were used as normal and elevated values.

View Article and Find Full Text PDF

Comparison of pregnancy outcomes in amniocentesis recipients with normal and abnormal maternal serum analytes.

Cell Mol Biol (Noisy-le-grand)

November 2024

Reproductive Health Research Center, Department of Midwifery and Reproductive Health, Al-Zahra Hospital, Guilan University of Medical Sciences, Rasht, Iran.

Considering the relatively high frequency of genetic disorders associated with negative pregnancy outcomes, in this research, adverse pregnancy outcomes in amniocentesis patients were compared between two groups with normal and abnormal maternal serum analytes. This retrospective cohort study was conducted on singleton pregnant women who underwent amniocentesis and had fetuses with normal chromosomes at the perinatology clinic in Rasht. Eligible patients were divided into two groups of 307 people with normal and abnormal maternal serum analytes based on laboratory screening results.

View Article and Find Full Text PDF

Objective: To retrospectively analyze the results of second-trimester serological prenatal screening and explore the factors which may influence the false-positive rate (FPR).

Methods: From January 2013 to December 2022, false-positive samples with follow-up outcomes from 632,825 second-trimester serological prenatal screening samples tested at Sichuan Provincial Maternity and Child Health Care Hospital were selected as the study group, while true-negative samples were 1 : 1 matched as the control group by propensity-score matching (PSM). Univariate and binary logistic regression models were used to analyze the influencing factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!